(Hong Kong, 30 December 2025) — Hong Kong Science and Technology Parks Corporation (HKSTP) extends its congratulations to its park company, Insilico Medicine (3696.HK), a clinical-stage biopharmaceutical company powered by generative artificial intelligence, on its successful listing on the Main Board of the Hong Kong Stock Exchange (HKEX) on 30 December. The initial public offering (IPO) raised a total of HK$ 2.277 billion, marking the largest fundraising IPO by a biopharmaceutical company in the Hong Kong stock market this year.
Mr Terry Wong, CEO of HKSTP, said, “HKSTP is delighted with the successful listing of our park company, Insilico Medicine, on the Hong Kong Stock Exchange and witnessed its growth in our innovation and technology (I&T) ecosystem as well as its remarkable achievements on the global stage. We remain committed to advancing the development of the life and health technology sector and look forward to more park companies following in Insilico’s footsteps. Leveraging Hong Kong’s unique strengths in fundraising, R&D, talent development, and translating scientific research results to market-ready solutions as well as HKSTP’s experience in nurturing I&T startups and ecosystem, Hong Kong continues to further reinforce its position as a leading international I&T hub.”
Founded in 2014, Insilico Medicine is a global leader in biotechnology, pioneering the integration of AI and automation to expedite drug discovery and drive innovation in the life sciences. The company is committed to advancing human health and enabling longer, healthier lives around the world. Insilico Medicine currently operates across four continents and has established a R&D office at Hong Kong Science Park. It has pioneered a distinctive dual-engine management model that combines AI algorithm innovation with drug development expertise. This approach seamlessly integrates cutting-edge computational technologies with pharmaceutical R&D, driving progress while ensuring both efficiency and balance.
Since 2020, Insilico Medicine has launched and commercialised its end-to-end platform, Pharma.AI, which spans biology, generative chemistry, clinical development, and scientific research. Delivered as a modular software suite, the platform has supported a rapidly expanding global network of collaborations. To date, Insilico Medicine has signed software licensing agreements with 13 of the world's top 20 pharmaceutical companies.
With a strong commitment to open-source academic research and knowledge sharing, Insilico Medicine actively publishes academic research and collaborates with industry stakeholders to exchange technological breakthroughs and commercial outcomes. The company has published more than 300 peer-reviewed papers and holds over 700 patents. In recognition of its contributions, Insilico Medicine was ranked among the top 100 global corporate institutions in life and natural sciences research by the Nature Index 2024. In 2025, the company was further recognised by being selected for the international scientific journal Nature Biotechnology annual list of the top ten research breakthroughs and was featured on the journal’s cover.
HKSTP has built a thriving I&T ecosystem, supported 12 unicorn companies and brought together approximately 2,600 tech companies from 25 countries and regions, with 16,000 professionals engaging in R&D. HKSTP’s incubation programme provides comprehensive support to innovators in different stages of their entrepreneurship journey, fostering their rapid growth and create global impact.
